Loading...
ImmunityBio, Inc.
IBRX•NASDAQ
Healthcare
Biotechnology
$2.86
$-0.15(-4.98%)
ImmunityBio, Inc. (IBRX) Financial Performance & Income Statement Overview
Review ImmunityBio, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
2270.58%
↑ 2270.58%
Operating Income Growth
4.99%
↑ 4.99%
Net Income Growth
29.09%
↑ 29.09%
Operating Cash Flow Growth
-6.67%
↓ 6.67%
Operating Margin
-1003.83%
↓ 1003.83%
Gross Margin
86.56%
↑ 86.56%
Net Profit Margin
-1310.30%
↓ 1310.30%
ROE
64.88%
↑ 64.88%
ROIC
-123.12%
↓ 123.12%
ImmunityBio, Inc. (IBRX) Income Statement & Financial Overview
Review ImmunityBio, Inc.'s (IBRX) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $7.55M | $6.11M | $1.05M | $40000.00 |
| Cost of Revenue | $4.14M | $0.00 | $0.00 | $4.55M |
| Gross Profit | $3.41M | $6.11M | $1.05M | -$4.51M |
| Gross Profit Ratio | $0.45 | $1.00 | $1.00 | -$112.88 |
| R&D Expenses | $35.22M | $50.44M | $51.13M | $52.85M |
| SG&A Expenses | $41.73M | $35.92M | $49.25M | $37.83M |
| Operating Expenses | $76.95M | $86.36M | $100.38M | $90.68M |
| Total Costs & Expenses | $76.95M | $86.36M | $100.38M | $95.24M |
| Interest Income | $769000.00 | $638000.00 | $833000.00 | $160000.00 |
| Interest Expense | $37.57M | $40.25M | $39.02M | $37.49M |
| Depreciation & Amortization | $4.15M | $4.44M | $4.41M | $4.55M |
| EBITDA | -$40.12M | -$41.07M | -$91.16M | -$92.09M |
| EBITDA Ratio | -$5.31 | -$6.73 | -$87.07 | -$2302.20 |
| Operating Income | -$69.40M | -$80.25M | -$99.33M | -$95.20M |
| Operating Income Ratio | -$9.19 | -$13.14 | -$94.87 | -$2379.90 |
| Other Income/Expenses (Net) | $10.24M | -$5.50M | -$35.25M | -$38.93M |
| Income Before Tax | -$59.16M | -$85.75M | -$134.58M | -$134.13M |
| Income Before Tax Ratio | -$7.83 | -$14.04 | -$128.54 | -$3353.25 |
| Income Tax Expense | $17000.00 | $0.00 | $0.00 | -$21000.00 |
| Net Income | -$59.16M | -$85.73M | -$134.56M | -$134.11M |
| Net Income Ratio | -$7.83 | -$14.04 | -$128.52 | -$3352.72 |
| EPS | -$0.10 | -$0.14 | -$0.20 | -$0.20 |
| Diluted EPS | -$0.09 | -$0.14 | -$0.20 | -$0.20 |
| Weighted Avg Shares Outstanding | $733.20M | $695.89M | $686.94M | $672.83M |
| Weighted Avg Shares Outstanding (Diluted) | $734.54M | $697.96M | $686.94M | $672.83M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan